Recursion Pharmaceuticals RXRX Stock
Recursion Pharmaceuticals Price Chart
Recursion Pharmaceuticals RXRX Financial and Trading Overview
| Recursion Pharmaceuticals stock price | 3.47 USD |
| Previous Close | 3.59 USD |
| Open | 3.52 USD |
| Bid | 3.63 USD x 900 |
| Ask | 4.44 USD x 200 |
| Day's Range | 3.45 - 3.85 USD |
| 52 Week Range | 2.77 - 7.18 USD |
| Volume | 30.72M USD |
| Avg. Volume | 13.99M USD |
| Market Cap | 2.01B USD |
| Beta (5Y Monthly) | 1.047 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.16 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.64 USD |
RXRX Valuation Measures
| Enterprise Value | 1.32B USD |
| Trailing P/E | N/A |
| Forward P/E | -4.3129444 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 30.29136 |
| Price/Book (mrq) | 1.9627136 |
| Enterprise Value/Revenue | 19.881 |
| Enterprise Value/EBITDA | -2.634 |
Trading Information
Recursion Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.047 |
| 52-Week Change | -17.84% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 7.18 USD |
| 52 Week Low | 2.77 USD |
| 50-Day Moving Average | 3.28 USD |
| 200-Day Moving Average | 4.27 USD |
RXRX Share Statistics
| Avg. Volume (3 month) | 13.99M USD |
| Avg. Daily Volume (10-Days) | 20.31M USD |
| Shares Outstanding | 524.68M |
| Float | 513.06M |
| Short Ratio | 14.35 |
| % Held by Insiders | 2.27% |
| % Held by Institutions | 68.64% |
| Shares Short | 184.44M |
| Short % of Float | 36.84% |
| Short % of Shares Outstanding | 34.75% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1985.55% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.66% |
| Return on Equity (ttm) | -57.15% |
Income Statement
| Revenue (ttm) | 66.41M USD |
| Revenue Per Share (ttm) | 0.14 USD |
| Quarterly Revenue Growth (yoy) | -56.10% |
| Gross Profit (ttm) | -428739008 USD |
| EBITDA | -501225984 USD |
| Net Income Avi to Common (ttm) | -559776000 USD |
| Diluted EPS (ttm) | -1.16 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 654.47M USD |
| Total Cash Per Share (mrq) | 1.24 USD |
| Total Debt (mrq) | 72.38M USD |
| Total Debt/Equity (mrq) | 7.06 USD |
| Current Ratio (mrq) | 5.471 |
| Book Value Per Share (mrq) | 1.931 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -320952000 USD |
| Levered Free Cash Flow (ttm) | -177795632 USD |
Profile of Recursion Pharmaceuticals
| Country | United States |
| State | UT |
| City | Salt Lake City |
| Address | 41 South Rio Grande Street |
| ZIP | 84101 |
| Phone | 385 269 0203 |
| Website | https://www.recursion.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 600 |
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Q&A For Recursion Pharmaceuticals Stock
What is a current RXRX stock price?
Recursion Pharmaceuticals RXRX stock price today per share is 3.47 USD.
How to purchase Recursion Pharmaceuticals stock?
You can buy RXRX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Recursion Pharmaceuticals?
The stock symbol or ticker of Recursion Pharmaceuticals is RXRX.
Which industry does the Recursion Pharmaceuticals company belong to?
The Recursion Pharmaceuticals industry is Biotechnology.
How many shares does Recursion Pharmaceuticals have in circulation?
The max supply of Recursion Pharmaceuticals shares is 530.76M.
What is Recursion Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Recursion Pharmaceuticals PE Ratio is now.
What was Recursion Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Recursion Pharmaceuticals EPS is -1.16 USD over the trailing 12 months.
Which sector does the Recursion Pharmaceuticals company belong to?
The Recursion Pharmaceuticals sector is Healthcare.
Recursion Pharmaceuticals RXRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech US 700 Small Cap Index NQUS700SC | 2992.49 USD — |
-1.38
|
— — | 2986.86 USD — | 3018.97 USD — | — - | — — |
| US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG | 4054.02 USD — |
-0.25
|
— — | 4019.75 USD — | 4077 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}